These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23633539)

  • 1. Lenalidomide in the treatment of plasma cell dyscrasia: state of the art and perspectives.
    Palumbo A; Cavallo F
    Haematologica; 2013 May; 98(5):660-1. PubMed ID: 23633539
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of plasma cell dyscrasias with lenalidomide.
    Dimopoulos MA; Kastritis E; Rajkumar SV
    Leukemia; 2008 Jul; 22(7):1343-53. PubMed ID: 18509355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second to none.
    Rajkumar SV
    Blood; 2012 Aug; 120(8):1537-9. PubMed ID: 22918420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable hematologic complete responses can be achieved with lenalidomide in AL amyloidosis.
    Sanchorawala V; Finn KT; Fennessey S; Shelton A; Doros G; Zeldis JB; Seldin DC
    Blood; 2010 Sep; 116(11):1990-1. PubMed ID: 20847211
    [No Abstract]   [Full Text] [Related]  

  • 6. Lenalidomide in myeloma--a high-maintenance friend.
    Badros AZ
    N Engl J Med; 2012 May; 366(19):1836-8. PubMed ID: 22571206
    [No Abstract]   [Full Text] [Related]  

  • 7. Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
    Ozaki S; Harada T; Fujii S; Nakamura S; Miki H; Nakano A; Kagawa K; Takeuchi K; Abe M; Matsumoto T
    Int J Hematol; 2011 Feb; 93(2):257-259. PubMed ID: 21279817
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].
    Fuchida S; Okano A; Hatsuse M; Murakami S; Haruyama H; Shimazaki C
    Rinsho Ketsueki; 2012 Nov; 53(11):1937-9. PubMed ID: 23257677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide induced intrahepatic cholestasis in newly diagnosed patients of multiple myeloma.
    Jena RK; Swain TR; Kansurkar SS; Swain M
    Eur J Clin Pharmacol; 2012 May; 68(5):881-4. PubMed ID: 22127618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide for the treatment of B-cell malignancies.
    Chanan-Khan AA; Cheson BD
    J Clin Oncol; 2008 Mar; 26(9):1544-52. PubMed ID: 18285605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib and lenalidomide effective in myeloma.
    Cancer Biol Ther; 2007 Jan; 6(1):5. PubMed ID: 17612004
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide for multiple myeloma.
    Bertolini F
    N Engl J Med; 2012 Aug; 367(6):573; author reply 573-5. PubMed ID: 22873542
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide in multiple myeloma.
    Sirohi B; Powles R
    Expert Rev Anticancer Ther; 2009 Nov; 9(11):1559-70. PubMed ID: 19895240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
    Usmani SZ; Sexton R; Hoering A; Heuck CJ; Nair B; Waheed S; Al Sayed Y; Chauhan N; Ahmad N; Atrash S; Petty N; van Rhee F; Crowley J; Barlogie B
    Blood; 2012 Aug; 120(8):1597-600. PubMed ID: 22674807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
    Vallet S; Palumbo A; Raje N; Boccadoro M; Anderson KC
    Leuk Lymphoma; 2008 Jul; 49(7):1238-45. PubMed ID: 18452080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New immunomodulatory drugs in myeloma.
    Lacy MQ
    Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide in myelodysplastic syndrome and multiple myeloma.
    Shah SR; Tran TM
    Drugs; 2007; 67(13):1869-81. PubMed ID: 17722955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.